by now it has clearly been shown that Neuren's management, head...

by now it has clearly been shown that Neuren's management, head of Treagus, has chosen and tried to put the company as safe as possible from an acquisition and the choice of Acadia is the clearest demonstration in the fact that only a part of it has been granted. sharing of intellectual assets. if Treagus had hooked a big pharma certainly would have given much more in the face of early payments, perhaps many higher immediately, but reduced in the long term. having taken note of the very long time available to decide what to do, certainly and with conviction this company has preferred to give up a considerable value today to have much more tomorrow and this is decided only if you are sure it will happen. a big would have demanded optional power over the rest of intellectual property and for convenience, on the way, would have proposed a buyout; evidently to the conditions posed by Neuren, a big pharma is not interested in having only a marginal part; in the American biotech market we have rarely seen a partnership between a small bio and a big one to finalize a phase 3; otherwise the best and perfumed agreements are concluded between the two parties in a preclinical phase or after request to the FDA for the beginning of experimentation and for what concerns us it would be the perfect case for NNZ-2591.
we are paying on the market this choice more than the rest related to Acadia and all that is positive and negative behind. the management chose time ago what to do, precisely in October last year after the meeting with FDA. over a period of 15 months we have recorded a series of choices made by the company that, in light of what we know today, certify that we have married the growth project without leaving little or nothing outside. we had a fund that was practically empty and it was decided to raise capital from Walker, granting more than 19% of the company; then it was preferred an institutional that has been to the game up to a certain point already realizing a part of capital at the end of 2017 giving strategic sense to its investment. obviously, it was not decided to give excessive power to Walker who, in the face of short-term or postponed profit choices, certainly as a good shareholder and with a five-year participation, would have chosen the first one. then a market that has set a boring $ 3 price with low volumes, which was consolidated after the news of the NNZ-2591 patent; the market in this context was very likely to have believed in a full and thick agreement and today it was disappointed.
recently the engagement of three non-executive executives who have the ability to oversee Acadia's work, but even more to structure the company both for the commercial initiative of Trofinetide in markets other than North America, and perhaps above all, to guarantee skills and opportunities for the best experimental placement of NNZ-2591.
in conclusion, today we pay a speculative bubble mounted and never burst beyond the 3 $, but we have the vision without veils of Neuren's future strategy with a financial budget plan well outlined in numbers and timing. as I see it this is a great advantage that a mature market will seize. what is missing and what must be revealed is the awareness that Trofinetide is already completed and that it must bring the money necessary to grow quickly the younger brother 2591. evident with accounts in hand, even in the most optimistic forecasts the money for what he must face 2591 are insufficient, so a high-profile preclinical or maximum agreement is essential for a first phase. there is a great advantage that little transpire but very important, or that everything that has been done for Trofinetide with further study of toxicity for larger doses is already usable for 2591. I think this hidden value package is the element on which the company has long been working for a real, solid and mature change of pace, unlike the three attempts to break through the $ 3 registered in the last 3 years. all managers must be involved in share ownership with considerable shares; we need a retail under 50% of the float and with a more than conviction attitude to a long-term investment; we need US investments that by their nature invest only on the bilateral return prospects that today the company does not guarantee, but with 2591 .....
this is in principle my reading of how things are and what really can give a serious sense to my investment.